News Wire ~ 3rd Party Press Release
Company Developing Peanut Immunotherapy Toothpaste Meets with FDA
"INT301 has the potential to be the first allergy immunotherapy treatment that easily integrates into a person’s daily routine."
Study: Children with Food Allergy at Lower Risk for Complicated Appendicitis
Children with allergies may have a lower risk because their immunological response is different from that of non-allergic children.
FDA Grants Fast Track Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis
"A significant milestone for INSYS and our clinical development of this novel drug-device combination.”
In Response to Shortage, AUVI-Q® Will Be Available in Canada Starting September 7
Interim order by Minister of Health authorizes the importation and sale.
EAT Launches ‘Give and Go’ Public Service Announcement
PSA will air in movie theaters and online to promote action when anaphylactic reactions occur.
Pfizer Issues Statement Extending the Expiration Date for Select Lots of EpiPen
To address shortages of EpiPen, Pfizer is coordinating with FDA to extend the expiration dates of specific lots of EpiPen® 0.3 mg Auto-Injectors.
FDA Approves First Generic Version of EpiPen
The FDA today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector.
Kaléo Confirms US Availability of Auvi-Q Epinephrine Auto-Injector
AUVI-Q is not affected by the manufacturing delays reported to the FDA by other epinephrine auto-injector manufacturers.
FDA Grants Xolair Breakthrough Therapy Designation for Food Allergies
Breakthrough Therapy Designation was granted on the basis of data from seven clinical studies assessing the efficacy and safety of Xolair against a range of food allergens including peanut, milk, egg and others.
Asbestos Found in Popular Crayon Brand
Lab results show many supplies safe, but some contain asbestos, lead and other hazardous chemicals.
